Related Experiment Video
Updated: Jan 24, 2026

Depletion of Specific Cell Populations by Complement Depletion
Published on: February 5, 2010
[How often do SmPCs Contain Contraindications and Special Warnings that are Specific for the Paediatric Population]
Stefan Wimmer1,2, Wolfgang Rascher1, Antje Neubert1
1Department of Paediatrics and Adolescent Medicine, Universitätsklinikum, Erlangen.
Insights
Many medicines have contraindications for pediatric patients due to lack of data, not inherent risks. The EU Paediatric Regulation has not significantly increased pediatric studies for off-patent drugs.
Area of Science:
- Pharmacovigilance
- Pediatric Pharmacology
- Drug Safety
Background:
- Off-label prescribing is common in pediatric patients, with many medications lacking age-specific licensing.
- A significant proportion of commonly used drugs for newborns are not approved for this age group.
Purpose of the Study:
- To analyze German Summary of Product Characteristics (SmPCs) for contraindications and warnings specific to pediatric age groups.
- To identify patterns in these contraindications based on age, drug class, and route of administration.
Main Methods:
- Systematic review of all available German SmPCs.
- Extraction and evaluation of information on pediatric age groups from 'Contraindications' and 'Special warnings and precautions' sections.
- Analysis of results by age group, Anatomical Therapeutic Chemical (ATC) classification, and route of application.
Main Results:
- Out of 13,547 SmPCs reviewed, 15.8% contained contraindications for at least one pediatric age group.
- 42.4% of medicinal products had contraindications or warnings for pediatric patients, with 12.4% affecting all patients under 18.
- Preterm infants were particularly affected (41.9%), as were contrast media (89.0%), cough and cold preparations (86.2%), and corticosteroids (88.2% topical, 86.6% systemic).
Conclusions:
- Pediatric contraindications in SmPCs likely stem from insufficient data and lack of age-specific formulations, rather than pharmacokinetic/pharmacodynamic differences.
- The EU Paediatric Regulation has had a limited impact on encouraging pediatric studies for off-patent medicines.
Background:
3.2-3.8% of all medicine prescriptions for minor outpatients are off-label only because of the patients' age group. The younger, the more patients are affected by this issue. Only one fifth of the most commonly used medicines for newborns are licensed for this age group. The aim of this study is to analyse all German SmPCs whether they contain contraindications and warnings that specifically concern paediatric patients.
Methods:
All available SmPCs were processed to search the sections Contraindications and Special warnings and precautions for information on paediatric age groups. Results were evaluated for differences between age groups, ATC classification and routes of application.
Results:
13547 SmPCs (22863 medicinal products) were evaluated. For 3603 (15.8%) medicinal products the SmPC contained contraindications for at least one paediatric age group. For 9687 (42.4%) medicinal products contraindications or warnings were found, including 2833 (12.4%) where all patients below 18 years were affected. Preterms were particularly affected (n=9581, 41.9%) as well as the ATC therapeutic subgroups contrast media (89.0%), cough and cold preparations (86.2%) and Corticosteroids (topical 88.2%, systemic 86.6%). Concerning liquids for oral use the proportion was higher than average (58.2%).
Conclusion:
It can be assumed that for most medicinal products the contraindications for paediatrics result from a lack of data and age specific formulations rather than from pharmacokinetic or -dynamic differences in paediatric patients. The EU Paediatric Regulation did not significantly stimulate the conduction of paediatric studies in off-patent medicines to this day.
Related Concept Videos
Special Staining Techniques
Introduction to Special Senses
Conservation of Small Populations
What is Population Genetics?
Population Growth
Specialized Characteristics of Cardiac Muscles
Cardiac muscle cells are smaller than skeletal muscles, averaging 10–20 mm in diameter and 50–100 mm in length. However, they have large energy demands for continuous contraction and relaxation. This energy is almost exclusively derived from aerobic metabolism of energy...

